Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.

@article{Pfister2009OutcomePI,
  title={Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.},
  author={Stefan M. Pfister and Marc Remke and Axel Benner and Frank Mendrzyk and Grischa Toedt and Joerg Felsberg and Andrea Wittmann and Frauke Devens and Nicolas Ulrich Gerber and Stefan Joos and Andreas E Kulozik and Guido Reifenberger and Stefan Rutkowski and Otmar Dieter Wiestler and Bernhard Radlwimmer and Wolfram G. Scheurlen and Peter Lichter and Andrey Korshunov},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 10},
  pages={1627-36}
}
PURPOSE Medulloblastoma is the most common malignant brain tumor in children. Current treatment decisions are based on clinical variables. Novel tumor-derived biomarkers may improve the risk stratification of medulloblastoma patients. PATIENTS AND METHODS A model for the molecular risk stratification was proposed from an array-based comparative genomic hybridization (array-CGH) screen (n = 80). Fluorescence in situ hybridization (FISH) analyses for chromosome arms 6q, 17p, and 17q and the MYC… CONTINUE READING